Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CC-92252 in Healthy Volunteers and Psoriasis
NCT03971825Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jul 2018
- Primary completion
- Aug 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CC-92252 in plaque psoriasis (2 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events. Started Jul 2018; status: terminated.
02
Drugs
CC-92252
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03971825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971825.